Drug · DIN 02308215
RELISTOR
12 MG/0.6 ML SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 18, 2021; first marketed May 7, 2008.
- Drug Identification Number (DIN)
- 02308215
- Company (DIN owner)
- Salix Pharmaceuticals IncBridgewater, New Jersey, United States
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Methylnaltrexone bromide A06AH01
- Class
- Human
- Record last updated
- July 30, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| METHYLNALTREXONE BROMIDE | 20 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 3, 2012: NOC 13013New Drug Submission (NDS) · Manufacturer name change
- September 29, 2010: NOC 11752New Drug Submission (NDS) · Manufacturer name change
- March 28, 2008: NOC 9445New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “relistor”. A notice may cover another product or only some lots: read it to see what it covers.
- RELISTOR (Methylnaltrexone Bromide) Subcutaneous Injection – Association with Gastrointestinal Perforation – For the PublicAugust 3, 2010 · Drugs · New safety information
- RELISTOR (methylnaltrexone bromide) Subcutaneous Injection - Association with Gastrointestinal Perforation - For Health ProfessionalsAugust 3, 2010 · Drugs
Other DINs named RELISTOR
- DIN 02356481 · Approved
- DIN 02356503 · Approved